BMY vs. MRK
Compare and contrast key facts about Bristol-Myers Squibb Company (BMY) and Merck & Co., Inc. (MRK).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BMY or MRK.
Correlation
The correlation between BMY and MRK is 0.51, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
BMY vs. MRK - Performance Comparison
Key characteristics
BMY:
0.55
MRK:
-1.34
BMY:
1.05
MRK:
-1.78
BMY:
1.13
MRK:
0.76
BMY:
0.34
MRK:
-0.87
BMY:
1.69
MRK:
-1.65
BMY:
9.70%
MRK:
19.22%
BMY:
29.88%
MRK:
23.69%
BMY:
-70.62%
MRK:
-68.62%
BMY:
-21.60%
MRK:
-33.50%
Fundamentals
BMY:
$117.65B
MRK:
$218.22B
BMY:
-$4.41
MRK:
$6.74
BMY:
1.36
MRK:
0.79
BMY:
$36.44B
MRK:
$48.39B
BMY:
$23.27B
MRK:
$39.64B
BMY:
$11.69B
MRK:
$19.98B
Returns By Period
In the year-to-date period, BMY achieves a 3.36% return, which is significantly higher than MRK's -12.41% return. Over the past 10 years, BMY has underperformed MRK with an annualized return of 2.27%, while MRK has yielded a comparatively higher 7.97% annualized return.
BMY
3.36%
-2.73%
9.06%
16.35%
4.35%
2.27%
MRK
-12.41%
-5.86%
-20.28%
-31.52%
6.74%
7.97%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
BMY vs. MRK — Risk-Adjusted Performance Rank
BMY
MRK
BMY vs. MRK - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Bristol-Myers Squibb Company (BMY) and Merck & Co., Inc. (MRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
BMY vs. MRK - Dividend Comparison
BMY's dividend yield for the trailing twelve months is around 5.26%, more than MRK's 3.66% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 4.22% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% |
MRK Merck & Co., Inc. | 3.66% | 3.14% | 2.72% | 2.52% | 3.41% | 3.03% | 2.48% | 2.60% | 3.36% | 3.14% | 3.43% | 3.12% |
Drawdowns
BMY vs. MRK - Drawdown Comparison
The maximum BMY drawdown since its inception was -70.62%, roughly equal to the maximum MRK drawdown of -68.62%. Use the drawdown chart below to compare losses from any high point for BMY and MRK. For additional features, visit the drawdowns tool.
Volatility
BMY vs. MRK - Volatility Comparison
Bristol-Myers Squibb Company (BMY) has a higher volatility of 8.38% compared to Merck & Co., Inc. (MRK) at 6.99%. This indicates that BMY's price experiences larger fluctuations and is considered to be riskier than MRK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
BMY vs. MRK - Financials Comparison
This section allows you to compare key financial metrics between Bristol-Myers Squibb Company and Merck & Co., Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities